MAPT and Alzheimer disease: Besides, an 2′MOE-modified ASO called IONIS MAPTRx (ISIS 814907) has been evaluated in a phase I/II study in patients with mild AD (NCT03186989), as it highly reduced the expression of tau protein through targeting MAPT mRNA.